机构名称：
¥ 1.0
定价方法摘要：Bluebird Bio's Lyfgenia代表了迄今为止对生命的疾病（即镰状细胞疾病或SCD）的基本范式转变，迄今为止，对受影响的患者及其家人的治疗方案非常有限。蓝鸟生物基于lyfgenia设定的四个关键价值驱动因素的WAC价格：源自Lyfgenia的临床益处（即resolution of vaso-occlusive events [VOEs] and sustained improvement in total hemoglobin levels), the impact of LYFGENIA on patient and caregiver well-being, relative cost impact of LYFGENIA with current standard of care (SoC] (hydroxyurea, red blood cell exchange) [note that newer disease-modifying therapies such as voxelotor are not yet considered SoC), and the broader societal impact of Lyfgenia包括患者及其护理人员的未来贡献。
Bluebird Bio，Inc。
主要关键词
相关文件推荐
